Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 20;5(9):82.
doi: 10.3390/jcm5090082.

Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery

Ji Young Yhee  1 , Jintaek Im  2 , Richard Seonghun Nho  3
Affiliations
Review

Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery

Ji Young Yhee et al. J Clin Med. .

Abstract

Chronic lung diseases include a variety of obstinate and fatal diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and lung cancers. Pharmacotherapy is important for the treatment of chronic lung diseases, and current progress in nanoparticles offers great potential as an advanced strategy for drug delivery. Based on their biophysical properties, nanoparticles have shown improved pharmacokinetics of therapeutics and controlled drug delivery, gaining great attention. Herein, we will review the nanoparticle-based drug delivery system for the treatment of chronic lung diseases. Various types of nanoparticles will be introduced, and recent innovative efforts to utilize the nanoparticles as novel drug carriers for the effective treatment of chronic lung diseases will also be discussed.

Keywords: biodistribution; lung diseases; nanoparticle; pulmonary delivery; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Enhanced permeation of disease-related blood vessels and targeted delivery of intravenously injected nanoparticles.
Figure 2
Figure 2
Size-dependent regional deposition of micro- and nanoparticles within the respiratory system after the inhalation. Reproduced from Reference [50] with permission from The Royal Society of Chemistry.
Figure 3
Figure 3
Schematic illustration of various nanoparticles classified based on their building components and characteristic structures.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization . Global Tuberculosis Report 2013. World Health Organization; Geneva, Switzerland: 2013. pp. 6–27.
    1. World Health Organization . Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. World Health Organization; Geneva, Switzerland: 2007. pp. 12–36.
    1. Halbert R.J., Natoli J.L., Gano A., Badamgarav E., Buist A.S., Mannino D.M. Global burden of COPD: Systematic review and meta-analysis. Eur. Respir. J. 2006;28:523–532. doi: 10.1183/09031936.06.00124605. - DOI - PubMed
    1. Masoli M., Fabian D., Holt S., Beasley R., Global Initiative for Asthma P The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478. doi: 10.1111/j.1398-9995.2004.00526.x. - DOI - PubMed
    1. Ley B., Collard H.R. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 2013;5:483–492. doi: 10.2147/CLEP.S54815. - DOI - PMC - PubMed

LinkOut - more resources